Treatment-related AEs
| AE . | Grades 1 and 2, No. (%) . | Grades 3 and 4, No. (%) . |
|---|---|---|
| Fatigue | 12 (44.4%) | 5 (18.5%) |
| Skin rash | 9 (33.3%) | 0 (0%) |
| Upper respiratory infection | 6 (22.2%) | 2 (7.4%) |
| Pneumonia | 0 (0%) | 3 (11.1%) |
| Increased creatinine | 5 (18.5%) | 2 (7.4%) |
| Myelosuppression | 16 (59.3%) | 7 (25.9%) |
| Thromboembolic events | 0 (0%) | 0 (0%) |
| AE . | Grades 1 and 2, No. (%) . | Grades 3 and 4, No. (%) . |
|---|---|---|
| Fatigue | 12 (44.4%) | 5 (18.5%) |
| Skin rash | 9 (33.3%) | 0 (0%) |
| Upper respiratory infection | 6 (22.2%) | 2 (7.4%) |
| Pneumonia | 0 (0%) | 3 (11.1%) |
| Increased creatinine | 5 (18.5%) | 2 (7.4%) |
| Myelosuppression | 16 (59.3%) | 7 (25.9%) |
| Thromboembolic events | 0 (0%) | 0 (0%) |